Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Juno boosts cellular therapy partnerships
by Lisa M. Jarvis
April 18, 2016
| A version of this story appeared in
Volume 94, Issue 16
Juno Therapeutics will collect $50 million now that Celgene has exercised an option to develop its cellular therapies targeting CD19 outside of North America and China. Juno’s CD19 portfolio includes three drug candidates; one, JCAR015, is in Phase II studies to treat acute lymphoblastic leukemia. Last year, Celgene paid $1 billion for the rights to opt in to Juno’s cellular therapies. Separately, Juno and WuXi AppTec have started JW Biotechnology in China to pair Juno’s cellular therapy technology with WuXi’s R&D and manufacturing expertise.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X